Nov 3, 2021
During the October 20, 2021, Senate Finance Hearing, Health Insurance Coverage in America: Current and Future Role of Federal Programs, the areas where each party agrees to disagree are stark, but the places where change for patients is possible exists. It is our aim...
Jun 11, 2021
On May 14th, 2021, ICER released a Draft Evidence Report entitled, “JAK Inhibitors and Monoclonal Antibodies for the Treatment of Atopic Dermatitis.” Patients Rising Now responded to the request for comments on the report. The comments noted that complex health...
May 27, 2021
On May 5, 2021, ICER released its Draft Evidence Report entitled, “Aducanumab for Alzheimer’s Disease.” Patients Rising Now submitted comments on the draft report. As stated in the comments, the goal for researchers and clinicians – and hope for patients – is to...
Mar 11, 2021
Comments on ICER’s February 11, 2021 Draft Evidence Report “Anti B-Cell Maturation Antigen CAR T-cell and Antibody Drug Conjugate Therapy for Heavily Pre-Treated Relapsed and Refractory Multiple Myeloma”. Some of the concerns raised in the letter point out that...
Feb 19, 2021
On January 22, 2021, ICER released its Draft Evidence Report entitled, “Belimumab and Voclosporin for Lupus Nephritis: Effectiveness and Value.” Patients Rising Now submitted comments on the draft report. Some of the concerns raised in the letter include the...
Aug 21, 2019
Patients Rising NOW offers the following comments on ICER’s May 22nd draft report, “Deflazacort, Eteplirsen, and Golodirsen for Duchenne Muscular Dystrophy.” Our comments about the draft report are organized below into sections concerning: Patient and Family...
